Germline genetics and different responses to different types of ADT

Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen deprivation therapy and related factors. … READ MORE …

How close are we really to “precision medicine” for cancer care?

A newly published paper in the journal JCO Precision Oncology confirms what many of us may have suspected — that the practical application of somatic tissue testing to clinical decision-making was low prior to 2015 . … READ MORE …

Genetics, genomics, targeted therapy, and the costs of care

A new paper in a new journal argues that all men diagnosed with advanced forms of prostate cancer should now, routinely, be undergoing tumor and germline DNA profiling … READ MORE …

Patients with certain KLK-6 mutations at risk for aggressive forms of prostate cancer

A newly published article in the Journal of the National Cancer Institute has suggested that men carrying a particular genetic mutation in the kallikrein 6 gene (KLK-6) have an increased risk for aggressive, clinically significant prostate cancer. … READ MORE …

The cost and the effectiveness of genomic testing for prostate cancer risk

As regular readers will be well aware, there are now several different tests available that can be used to assess risk for low- and very low-risk forms of prostate cancer at time of diagnosis (as opposed to clinically significant forms that need early treatment). … READ MORE …

Just how accurate are current genetic/genomic tests in the diagnosis and prognosis of prostate cancer?

As we have pointed out regularly over the years, all prostate cancers are by no means the same. And a recently published paper in European Urology makes the inherent diversity in the subtypes of prostate cancer even clearer — even within any one specific patient. … READ MORE …

Informed patient counseling and the effect on PSA testing

We know that a family history of prostate cancer and the presence of certain genetic/genomic markers are associated with increased risk for prostate cancer in general and for some types of clinically significant prostate cancer in particular. … READ MORE …